secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001683168-23-003169
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte announces $35M convertible preferred financing and tender offer for up to 7.75M shares at $3.25
--------------------------------------------------------------------------------

- Raises ~$35M via sale of 35,000 Series B convertible preferred shares and warrants to existing investors.
- Preferred stock convertible at $4.00/share; warrants exercisable at $4.00/share for up to 8.75M shares, expiring in 5 years.
- Commences cash tender offer for up to 7,750,000 common shares at $3.25/share, expiring June 9, 2023.
- Tender offer funded from cash on hand; CEO cites no definitive timeframe for pancreatic cancer asset.
- Preferred shares carry 4% annual dividend, redeemable monthly starting Nov 9, 2023; subject to Nasdaq approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/0001683168-23-003169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer